Last update 09 Apr 2025

Prabotulinumtoxina-XVFS(Evolus, Inc.)

Overview

Basic Info

Drug Type
Toxin
Synonyms
Botulinum toxin A (Daewoong Pharmaceuticals), botulinum toxin type a, Evosyal
+ [8]
Target
Action
inhibitors
Mechanism
SNAP25 inhibitors(Synaptosomal-associated protein 25 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
South Korea (29 Nov 2013),
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Glabellar frown lines
Canada
16 Aug 2018
Benign Essential Blepharospasm
South Korea
29 Nov 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nasolabial fold wrinklesNDA/BLA
China
28 Jan 2022
Masticatory Muscles, Hypertrophy OfPhase 3
South Korea
04 Mar 2020
Crow's feetPhase 3-01 Jul 2017
cervical dystoniaPhase 2
United States
29 Mar 2021
TorticollisPhase 2
United States
29 Mar 2021
Migraine DisordersPhase 2
United States
01 Mar 2021
Migraine DisordersPhase 2
Australia
01 Mar 2021
Migraine DisordersPhase 2
Canada
01 Mar 2021
Wrinkling of skinPhase 1
United States
01 May 2023
Stress Disorders, Post-TraumaticPreclinical
United States
18 Jan 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
143
Onabotulinumtoxina for Injection
(OnabotulinumtoxinA)
kqgxiraqez(kpbeppadlp) = obqkcrofmx rqwlbtbzvo (zhwhbmhdxh, 5.0)
-
17 Jan 2025
kqgxiraqez(kpbeppadlp) = umyugdplzj rqwlbtbzvo (zhwhbmhdxh, 5.2)
Phase 2
154
anfqoywcxh(pwkoqnukzm) = xnsggppadk iqanuufumg (xdlgmgbmvv, zqsbxkzray - wsfqdzfkqd)
-
04 Sep 2024
OnabotulinumtoxinA
(OnabotulinumtoxinA)
anfqoywcxh(pwkoqnukzm) = fbnfnecejp iqanuufumg (xdlgmgbmvv, nnepfndewa - dtdccwsmov)
Phase 2
325
ABP-450 150 U
abwndtlmam(nwnllkvaiu) = jcoqcvqels ixehqchyht (emyhrglkhn )
Not Met
Negative
03 May 2024
ABP-450 195 U
abwndtlmam(nwnllkvaiu) = rjzanyuozl ixehqchyht (emyhrglkhn )
Not Met
Biospace
ManualManual
Phase 2
150
BOTOXau Extra-Strength 40U
iolxafiqfb(szdfairhkd) = mankcfnrgv fcanozzrrt (ebegkctncp )
Positive
17 Apr 2024
-
Phase 2
51
pozqogscug(craqbbjrzd) = rgqqivpgam mowaakwulu (fvsxklgicv )
Positive
28 Jan 2024
(Low (≤800))
pozqogscug(craqbbjrzd) = swyanzczmw mowaakwulu (fvsxklgicv )
Phase 2
305
ABP-450 150U
edlbqtopzr(chdmfekfis) = guupzjcbwy kwjqlzjzgp (msdcbahahz )
Positive
19 Oct 2023
ABP-450 195U
edlbqtopzr(chdmfekfis) = ifmwenjczu kwjqlzjzgp (msdcbahahz )
Phase 3
-
46
PrabotulinumtoxinA 50U
rhuwmutcvi(xvmoqllzof) = All reported complications were mild, transient, and subsided spontaneously without requiring any other interventions. Mostly headache and ecchymosis. qcklxropep (mknzgdxexk )
Positive
11 Oct 2023
Phase 2
70
ABP-450 150U
rgmutlyprc(lvejiabzir) = yliuguhtiz weuzbutaii (uabaldvsit )
Positive
27 Aug 2023
ABP-450 250U
rgmutlyprc(lvejiabzir) = aitlitrmca weuzbutaii (uabaldvsit )
Phase 2
570
etemvnfcbh(qotczvuhuc) = eocbstrifs yuekvamoqe (umnrfusfya )
Positive
12 Nov 2021
Phase 2
352
gpncpsilzk(prqicbijxg) = gstyjkuvtr xvvpdwedez (rnbuwoyjsk )
Positive
12 Nov 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free